Clinical Trials

Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug

Bionomics has announced that further data analysis of its phase 2 post traumatic stress disorder (PTSD) trial demonstrated the potential for significant patient benefit when drug exposure is adequate.

Bavencio plus Inlyta improves median PFS in renal carcinoma study

Pfizer and Merck have announced that Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival (PFS) in renal carcinoma study.

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).

Boehringer Ingelheim, IBM to integrate blockchain technology into clinical trials

Boehringer Ingelheim (Canada) and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials.

Gilead’s liver disease drug selonsertib fails to meet primary endpoint in Stellar-4 study

Gilead Sciences has announced topline data from the phase 3 Stellar-4 study of its liver disease treatment selonsertib in compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).

NeoTX enters into immuno-oncology clinical trial collaboration with AstraZeneca

NeoTX Therapeutics has entered into a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox in combination with IMFINZI (durvalumab).

Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial

Moderna has announced the dosing of the first subject in a phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.

Eisai, Purdue Pharma present efficacy and safety data from second phase 3 study of lemborexant

Eisai and Purdue Pharma announced six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.

Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant

Verseon has started dosing of its lead blood thinner candidate VE-1902 in a phase 1 trial held in healthy volunteers at Nucleus Network in Melbourne, Australia.